Literature DB >> 31580939

Prevalence of healthcare-associated infections and antimicrobial use in China: Results from the 2018 point prevalence survey in 189 hospitals in Guangdong Province.

Yu Zhang1, Zhen-Feng Zhong2, Shu-Xian Chen3, Dian-Rong Zhou1, Zheng-Kang Li4, Yue Meng4, Jing-Fang Zhou4, Tie-Ying Hou5.   

Abstract

BACKGROUND: Limited data on healthcare-associated infections (HAIs) are available from the developing world, thus a point prevalence survey was conducted to determine the prevalence of HAIs and antimicrobial use in Guangdong Province, China.
METHODS: A standardized methodology for point prevalence surveys on HAIs and antimicrobial use has been developed by the Chinese Nosocomial Infection Control and Quality Improvement Center. The prevalence of HAIs, antimicrobial use, and baseline hospital-level variables were collected in 189 hospitals from June 2017 to May 2018.
RESULTS: Of 5 868 147 patients, 72 976 had one or more HAIs (1.24%), with 82 700 distinct HAIs. The prevalence rates of device-associated infections, including ventilator-associated pneumonia, catheter-associated urinary tract infection, and central line-associated bloodstream infection were 7.92, 2.06, and 0.63 per 1000 catheter-days, respectively. A total of 10 591 (0.18%) HAIs caused by multidrug-resistant organisms were identified. Carbapenem non-susceptibility rates were highest in Acinetobacter species (53.86%) and Pseudomonas aeruginosa (21.60%). Forty-six percent (2 712 258/5 868 147) of inpatients were receiving at least one antimicrobial during this survey.
CONCLUSIONS: This survey indicated the relatively lower prevalence of HAIs but higher antimicrobial using in Guangdong Province compared with other mid to low-income and high-income countries. Further studies are warranted to elucidate which HAI-related indicators are the best measures of HAI performance and thus allow improvements leading to better patient outcomes.
Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Antimicrobial use; China; Healthcare-associated infection; Multidrug-resistant organism; Point prevalence survey

Mesh:

Substances:

Year:  2019        PMID: 31580939     DOI: 10.1016/j.ijid.2019.09.021

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  3 in total

1.  Healthcare-associated infections and antimicrobial use in surgical wards of a large urban central hospital in Blantyre, Malawi: a point prevalence survey.

Authors:  Gabriel Kambale Bunduki; Nicholas Feasey; Marc Y R Henrion; Patrick Noah; Janelisa Musaya
Journal:  Infect Prev Pract       Date:  2021-07-24

2.  Incidence of Healthcare-Associated Infections (HAIs) and the adherence to the HAIs' prevention strategies in a military hospital in Alkharj.

Authors:  Nehad J Ahmed; Abdul Haseeb; Emad M Elazab; Hamed M Kheir; Azmi A Hassali; Amer H Khan
Journal:  Saudi Pharm J       Date:  2021-08-04       Impact factor: 4.330

Review 3.  Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam.

Authors:  Adam B Shapiro; Samir H Moussa; Sarah M McLeod; Thomas Durand-Réville; Alita A Miller
Journal:  Front Microbiol       Date:  2021-07-19       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.